We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long term responders in frontline multiple myeloma—exception vs expectation of the modern era.
- Authors
Baljevic, Muhamed; Sborov, Douglas W.; Kumar, Shaji K.
- Abstract
This article discusses the advancements in the treatment of multiple myeloma (MM) over the past two centuries. The introduction of various drugs and stem cell transplantation has improved survival rates and quality of life for patients. However, there is still a group of patients with high-risk disease who have limited survival. The addition of certain monoclonal antibodies to treatment regimens has shown promise, and new therapies may further improve outcomes. The article also includes a table summarizing recent studies on treatment regimens for newly diagnosed MM. The study analyzed the characteristics of long-term responders (LTRs) who achieved a prolonged progression-free survival (PFS) of at least 8 years following stem cell transplantation. LTRs were found to be younger, have lower disease burden, achieve better response rates, and more often receive post-transplant maintenance compared to non-LTRs. However, MM remains incurable for most patients, and the leading causes of death among LTRs were disease progression and second primary malignancies. The authors suggest that new approaches and therapies may increase the proportion of LTRs in the future.
- Subjects
MULTIPLE myeloma; HEMATOPOIETIC stem cell transplantation
- Publication
Blood Cancer Journal, 2024, Vol 14, Issue 1, p1
- ISSN
2044-5385
- Publication type
Editorial
- DOI
10.1038/s41408-024-01100-z